EGFR and colorectal cancer: Cetuximab (Cmab) is an anti-epidermal growth factor receptor (EGFR) antibody that has been shown to effectively combine with cytotoxic chemotherapy as first-, second- or third-line treatment against wild-type KRAS colorectal cancer (1–3).